US patent office seeks to reinstate suspended rule on application size
This article was originally published in SRA
Executive Summary
The US Patent and Trademark Office has voiced its arguments before the US Court of Appeals for the Federal Circuit in an effort to reinstate a suspended final rule that had sought to limit the size of patent applications1,2. The controversial rule was opposed by the pharmaceutical, biotech and medical technology industry associations, which feared that it would have stifled innovation and stood in the way of obtaining adequate patent protection.